KIRKLAND – Pfizer Canada ULC announced that Health Canada approved BEQVEZ (fidanacogene elaparvovec), an adeno-associated viral (AAV) vector-based gene therapy for the treatment of adults (aged 18 years or older) with moderately severe to severe hemophilia B (congenital Factor IX (FIX) deficiency) who are negative for neutralizing antibodies to variant AAV serotype Rh74. “Pfizer has more than 30 years of …
The Canadian Skin of Colour & Diversity Scholarship program will provide funds for dermatology residents to implement their ideas on addressing care gaps among underrepresented Canadians. KIRKLAND – Together with the Skin Spectrum Summit, Pfizer Canada is pleased to announce the new Canadian Skin of Colour & Diversity Scholarship program to improve dermatological care for underrepresented populations, including those with …
